Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | UNG | P13051 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 2/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 7/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28607053 | 0.82 | ALDH1A1 (0.42) | ALDH1A1KDM4EMEN1CYP1A2GLA | |
| SCHEMBL3627607 | 0.82 | ALDH1A1 (0.42) | ALDH1A1KDM4EMEN1CYP1A2GLA | |
| SCHEMBL931068 | 0.80 | ALDH1A1 (0.52) | ALDH1A1KDM4EMEN1CYP1A2GLA | |
| SCHEMBL11591905 | 0.78 | PTPN1 (0.50) | ALDH1A1KDM4EMEN1CYP1A2GLA | |
| SCHEMBL2750024 | 0.78 | KDM4E (0.44) | ALDH1A1KDM4EMEN1CYP1A2GLA | |
| SCHEMBL22228081 | 0.77 | MEN1 (0.68) | ALDH1A1KDM4EMEN1CYP1A2GLA | |
| Ethylene SCHEMBL28494344 | 0.77 | ALDH1A1 (0.49) | ALDH1A1KDM4EMEN1CYP1A2GLA | |
| SCHEMBL4751251 | 0.77 | ALDH1A1 (0.48) | ALDH1A1KDM4EMEN1CYP1A2GLA | |
| SCHEMBL2747254 | 0.77 | ALDH1A1 (0.43) | ALDH1A1KDM4EMEN1CYP1A2GLA | |
| Propene SCHEMBL28492822 | 0.76 | ALDH1A1 (0.45) | ALDH1A1KDM4EMEN1CYP1A2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1701934-B1 | DISUBSTITUTED CHALCONE OXIMES HAVING RAR(Gamma)-RETINOID RECEPTOR ANTAGONIST ACTIVITY | ALLERGAN INC (US) | 2009-02-25 | — | — | EP | disclosed |
| US-7476673-B2 | Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors | ALLERGAN, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-7432388-B2 | Disubstituted chalcone oximes having RARγ retinoid receptor antagonist activity | ALLERGAN, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080097119-A1 | Disubstituted chalcone oximes having RARgamma retinoid receptor antagonist activity | TSANG KWOK Y | 2008-04-24 | — | — | US | disclosed |
| US-7253319-B2 | Disubstituted chalcone oximes having RARγ retinoid receptor antagonist activity | ALLERGAN, INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1704139-A1 | DISUBSTITUTED CHALCONE OXIMES AS SELECTIVE AGONISTS OF RAR y RETINOID RECEPTORS | Allergan, Inc. (US) | 2006-09-27 | — | — | EP | disclosed |
| EP-1701934-A2 | DISUBSTITUTED CHALCONE OXIMES HAVING RAR(Gamma)-RETINOID RECEPTOR ANTAGONIST ACTIVITY | Allergan, Inc. (US) | 2006-09-20 | — | — | EP | disclosed |
| US-20050165095-A1 | Disubstituted chalcone oximes having RARy retinoid receptor antagonist activity | ALLERGAN, INC. | 2005-07-28 | — | — | US | disclosed |
| WO-2005066116-A1 | DISUBSTITUTED CHALCONE OXIMES AS SELECTIVE AGONISTS OF RARϜ RETINOID RECEPTORS | ALLERGAN, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005066115-A2 | DISUBSTITUTED CHALCONE OXIMES HAVING RARϜ RETINOID RECEPTOR ANTAGONIST ACTIVITY | ALLERGAN, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050148590-A1 | Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors | ALLERGAN, INC. | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097119-A1 | Disubstituted chalcone oximes having RARgamma retinoid receptor antagonist activity | RARG, RARB, RARA | ALDH1A1 421/4885KDM4E 2765/4885MEN1 4867/4885 |
| US-20050165095-A1 | Disubstituted chalcone oximes having RARy retinoid receptor antagonist activity | RARB, RARG, RARA | ALDH1A1 398/4885KDM4E 2153/4885MEN1 4853/4885 |
| US-20050148590-A1 | Disubstituted chalcone oximes as selective agonists of RAR retinoid receptors | RARG, RXRG, RARB | ALDH1A1 1103/4885KDM4E 3446/4885MEN1 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.